How Much Does Wegovy Cost in Washington in 2026?

Wegovy Retail Pricing in Washington

The manufacturer list price for Wegovy (semaglutide 2.4 mg) set by Novo Nordisk is $1,349 per month across all U.S. markets, including Washington state. This wholesale acquisition cost (WAC) applies to every maintenance-dose pen regardless of the pharmacy you visit in Seattle, Spokane, Tacoma, or anywhere else in the state. Cash-pay prices at Washington retail pharmacies cluster tightly around that same $1,349 figure.

That price covers four weekly 2.4 mg prefilled pens per carton. During the dose-escalation phase (weeks 1 through 16), the per-pen cost is the same even though the active dose is lower. The FDA-approved prescribing information for Wegovy specifies a 16-week titration from 0.25 mg to the 2.4 mg maintenance dose, meaning patients pay full price from the first injection [1]. Novo Nordisk does not offer a reduced WAC for the starter doses.

Pharmacy-to-pharmacy variation in Washington is minimal for cash-pay customers. A few independent pharmacies may negotiate slightly different acquisition costs from wholesalers, but the street price rarely drops below $1,300 without a coupon or discount card. Patients filling at chains like Costco, Fred Meyer, or Rite Aid (which still operates locations in Washington) should expect to pay within 3% of list price at the register.

One variable worth watching: Washington's Prescription Drug Affordability Board, established under SB 5532, has the authority to set upper payment limits on drugs it deems unaffordable. As of May 2026, Wegovy has not been selected for an affordability review, but GLP-1 receptor agonists as a class remain under discussion at the national level. If the board acts, WA pricing could diverge from other states.

Washington Medicaid Coverage for Wegovy

Washington Apple Health (Medicaid) covers Wegovy for chronic weight management, subject to prior authorization. This is a meaningful distinction. Many state Medicaid programs exclude anti-obesity medications entirely, but Washington opted to cover semaglutide 2.4 mg through its preferred drug list managed by the Health Care Authority (HCA).

Prior authorization criteria in Washington typically require documentation of a BMI ≥30 kg/m², or a BMI ≥27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The prescriber must also demonstrate that the patient has attempted lifestyle modifications (diet and exercise) for a minimum period, usually 3 to 6 months, before Wegovy will be approved. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity supports the use of semaglutide 2.4 mg as a first-line pharmacotherapy option for patients meeting BMI thresholds, noting that "the magnitude of weight loss achieved with semaglutide 2.4 mg exceeds that of all previously approved anti-obesity medications" [2].

Approval timelines vary. Some Washington Medicaid managed care organizations (MCOs), including Molina Healthcare of Washington and Coordinated Care, process Wegovy PAs within 72 hours. Others can take up to two weeks. If denied, patients have the right to appeal through the HCA's fair hearing process.

A practical consideration: Washington Medicaid covers Wegovy, but supply constraints can still create gaps. Patients with active PA approvals sometimes face pharmacy-level stockouts, particularly in rural counties east of the Cascades. Checking availability at multiple pharmacies before the PA is submitted can save time.

Private Insurance Coverage in Washington

Commercial insurance coverage for Wegovy in Washington is inconsistent across carriers and plan tiers. The state's largest insurers, including Premera Blue Cross, Regence BlueShield, and Kaiser Permanente Washington, each maintain their own formulary decisions regarding GLP-1 receptor agonists for weight management.

Premera Blue Cross covers Wegovy on select employer-sponsored plans but excludes it from many individual marketplace (ACA exchange) plans. Regence BlueShield has added Wegovy to some formularies with step therapy requirements, often mandating a trial of phentermine-topiramate or naltrexone-bupropion before approval. Kaiser Permanente Washington tends to cover Wegovy within its integrated system but requires an internal referral to a weight management program.

Self-insured employer plans represent a large portion of the commercially insured population in Washington. These plans are governed by ERISA, not state insurance mandates, so coverage depends entirely on what each employer selects. Large Washington-based employers like Amazon, Microsoft, and Starbucks have made varying decisions about GLP-1 coverage for weight management. Checking your specific plan's Summary of Benefits and Coverage (SBC) document is the only reliable way to confirm.

The clinical evidence supporting coverage is strong. In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg achieved 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo, a difference of 12.5 percentage points [3]. The STEP-3 trial, which combined semaglutide with intensive behavioral therapy, showed 16.0% weight reduction at 68 weeks versus 5.7% with placebo [4]. These results have pushed more insurers toward coverage, though the pace of formulary additions varies.

If your Washington insurer denies coverage, request the specific clinical criteria for approval. Many denials are overturned on appeal when the prescriber submits documentation that matches the insurer's PA criteria exactly.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings program for Wegovy that can reduce out-of-pocket costs to as little as $0 per month for eligible patients. This card works in Washington state. Eligibility requirements are straightforward but exclude certain populations.

To qualify, a patient must have commercial (private) insurance that covers Wegovy. The savings card does not apply to cash-pay purchases without insurance, and it cannot be used by patients enrolled in any federal healthcare program, including Medicare, Medicaid, Tricare, or VA benefits. Washington Medicaid enrollees are explicitly excluded.

For those who do qualify, the card covers up to $225 per 28-day fill, or the amount of the patient's copay, whichever is less. Some commercially insured patients in Washington report paying $0 with the card when their plan covers Wegovy at a specialty tier with a $50 to $200 copay. The savings card effectively zeroes out that copay.

The card is valid for up to 13 fills. After that, patients revert to their standard copay. Novo Nordisk has historically renewed the program on an annual basis, but the terms and maximum benefit amounts can change at any time. Patients should verify current terms directly at the Novo Nordisk patient assistance website or call 1-888-809-3942.

Compounded Semaglutide 2.4 mg in Washington

Compounded semaglutide 2.4 mg is available in Washington through licensed 503A compounding pharmacies. This is legal under both federal and Washington state pharmacy law, provided the pharmacy holds a valid Washington State Department of Health compounding license and operates under a patient-specific prescription from a licensed prescriber.

The typical cost for compounded semaglutide 2.4 mg in Washington ranges from $150 to $299 per month, with $199 representing a common price point. That is roughly 85% less than brand-name Wegovy.

There are real differences between compounded and brand-name product. Brand Wegovy uses Novo Nordisk's proprietary prefilled autoinjector with a fixed 2.4 mg dose in the maintenance pen. Compounded semaglutide is typically supplied as a multi-dose vial requiring the patient to draw up the correct volume with an insulin syringe. The active pharmaceutical ingredient is semaglutide base or semaglutide sodium salt, sourced from FDA-registered bulk chemical suppliers.

A key regulatory note: the FDA's guidance on 503A compounding permits compounding of copies of commercially available drugs when a prescriber determines that a change (such as a different concentration, formulation, or delivery method) produces a clinical difference for the individual patient [5]. Washington's Pharmacy Quality Assurance Commission does not impose additional restrictions beyond the federal framework for 503A pharmacies compounding semaglutide.

Quality assurance matters with compounded products. Patients should confirm that their compounding pharmacy conducts third-party potency and sterility testing on each batch. The pharmacy should be willing to provide certificates of analysis upon request. Choosing a pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB) adds another layer of oversight.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has stated: "The efficacy of semaglutide for weight management is well-established, but patients using compounded versions should ensure their pharmacy follows stringent sterility and potency standards" [6].

Telehealth Access to Wegovy in Washington

Washington state permits telehealth prescribing of Wegovy and compounded semaglutide. No in-person visit is required for the initial prescription. This has been the case since Washington expanded its telehealth parity law (RCW 48.43.735), which requires insurers to cover telehealth services at the same rate as in-person visits.

Several national telehealth platforms operate in Washington and prescribe semaglutide for weight management. Pricing through these platforms varies. Some charge a monthly membership fee ($50 to $149) on top of the medication cost. Others bundle the consultation into the price of compounded semaglutide. Patients should confirm that the prescribing clinician is licensed in Washington state, as the prescription must originate from a WA-licensed provider to be filled at a Washington pharmacy.

For brand-name Wegovy via telehealth, the prescription can be sent to any Washington retail or specialty pharmacy. The same insurance coverage and PA requirements apply regardless of whether the visit was in-person or virtual. The American Telemedicine Association's practice guidelines support telehealth-initiated prescribing of chronic disease medications, including anti-obesity pharmacotherapy, when appropriate clinical evaluation is conducted [7].

One practical advantage of telehealth in Washington: patients in rural areas of the state, including communities in the Palouse, Tri-Cities, or along the Olympic Peninsula, can access weight management specialists based in Seattle or Bellevue without a multi-hour drive. Given that Washington ranks 35th nationally in obesity prevalence at 31.4% according to CDC adult obesity data, expanding access points matters for population health outcomes [8].

How to Reduce Your Wegovy Cost in Washington

Multiple strategies can lower what you actually pay for semaglutide in Washington. The right approach depends on your insurance status.

Commercially insured patients: Start with the Novo Nordisk savings card. If your plan covers Wegovy at any tier, the card can eliminate your copay (up to $225 per fill). If your plan excludes Wegovy entirely, the card will not help.

Washington Medicaid enrollees: Your copay for Wegovy through Apple Health is $0 to $3 per fill once prior authorization is approved. The medication cost is covered by the state. Focus your effort on getting the PA approved rather than reducing the price.

Uninsured or cash-pay patients: Compounded semaglutide 2.4 mg at approximately $199 per month through a licensed Washington 503A pharmacy represents the most significant cost reduction. This is $1,150 less per month than brand Wegovy.

Medicare Part D enrollees: Coverage for anti-obesity medications under Medicare Part D remains limited. The Treat and Reduce Obesity Act has been reintroduced in Congress multiple times but has not passed as of 2026. Medicare beneficiaries in Washington who also have a type 2 diabetes diagnosis may be able to obtain semaglutide under the Ozempic brand (approved for glycemic control), which is covered by most Part D plans.

A lesser-known option: Novo Nordisk's Patient Assistance Program (PAP) provides Wegovy at no cost to uninsured patients with household income below 400% of the federal poverty level ($62,400 for a single individual in 2026). The application requires income documentation and a valid prescription. Processing takes 4 to 6 weeks.

The STEP-1 trial demonstrated that 86.4% of participants on semaglutide 2.4 mg lost ≥5% of body weight, and 50.5% lost ≥15%, compared to 31.5% and 4.9% with placebo, respectively [3]. These outcomes persist only with continued treatment. Stopping semaglutide leads to weight regain of approximately two-thirds of the lost weight within one year, as shown in the STEP-1 extension trial published in Diabetes, Obesity and Metabolism [9]. Cost planning for Wegovy should account for indefinite use rather than a fixed treatment course.

Washington-Specific Discount and Assistance Programs

Beyond manufacturer programs, Washington residents have a few additional resources for reducing prescription costs.

The Washington Prescription Drug Program (WPDP) negotiates supplemental drug rebates for certain state-funded programs. While WPDP primarily benefits state employees and other public program enrollees, its negotiated pricing can sometimes flow through to participating pharmacies for other customers.

Washington's Health Care Authority also administers the Apple Health for Workers with Disabilities program, which allows working individuals with disabilities to maintain Medicaid coverage even at higher income levels. If obesity-related disability qualifies a patient, Wegovy coverage through this program follows standard Apple Health formulary rules [10].

Community health centers across Washington, including those in the Community Health Plan of Washington network, may offer sliding-scale pricing for weight management services. The medication itself still requires a separate financial plan, but the clinical visits and monitoring can be reduced in cost.

The 2023 American Association of Clinical Endocrinology (AACE) consensus statement on obesity noted that "cost remains the single largest barrier to evidence-based obesity pharmacotherapy" and recommended that "payers prioritize coverage of anti-obesity medications with proven cardiovascular and metabolic benefits" [11]. Washington's decision to cover Wegovy through Medicaid aligns with that recommendation, though gaps remain in the commercial market.

Patients filling Wegovy at Costco pharmacies in Washington do not need a Costco membership to use the pharmacy (this is required by Washington state law for pharmacies inside membership clubs). Costco's pharmacy pricing is often 2% to 5% below other chains for brand medications, though the savings on a $1,349 product amount to roughly $27 to $67 per fill.

For patients weighing compounded versus brand semaglutide, the annual cost difference is substantial: $16,188 for brand Wegovy versus approximately $2,388 for compounded semaglutide at $199 per month. That is a $13,800 annual difference, assuming continuous maintenance dosing at 2.4 mg weekly.